SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001725160-23-000112
Filing Date
2023-05-10
Accepted
2023-05-10 07:04:15
Documents
14
Period of Report
2023-05-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zntl-20230510.htm   iXBRL 8-K 41847
2 EX-99.1 zntl_q12023earningsprv2.htm EX-99.1 64169
6 image_0.jpg GRAPHIC 5204
  Complete submission text file 0001725160-23-000112.txt   264795

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20230510.xsd EX-101.SCH 1902
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20230510_lab.xml EX-101.LAB 24849
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20230510_pre.xml EX-101.PRE 13046
8 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20230510_htm.xml XML 11258
Mailing Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39263 | Film No.: 23904287
SIC: 2834 Pharmaceutical Preparations